Inovio Pharmaceuticals (INO)
(Real Time Quote from BATS)
$9.75 USD
-0.41 (-4.04%)
Updated Apr 25, 2024 09:37 AM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Inovio Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 10 | 2 | 7 | 4 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 10 | 2 | 7 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | 145 | 278 | 303 | 132 | 115 |
Income After Depreciation & Amortization | -144 | -268 | -301 | -124 | -111 |
Non-Operating Income | 10 | -9 | 0 | -30 | -2 |
Interest Expense | 1 | 1 | 2 | 9 | 8 |
Pretax Income | -135 | -278 | -303 | -163 | -121 |
Income Taxes | 0 | 2 | 0 | 5 | 0 |
Minority Interest | 0 | 0 | 0 | -1 | -1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -135 | -280 | -304 | -167 | -121 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -135 | -280 | -304 | -166 | -119 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -133 | -263 | -295 | -119 | -106 |
Depreciation & Amortization (Cash Flow) | 11 | 4 | 6 | 5 | 6 |
Income After Depreciation & Amortization | -144 | -268 | -301 | -124 | -111 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 22.17 | 19.88 | 17.40 | 12.92 | 8.22 |
Diluted EPS Before Non-Recurring Items | -5.62 | -14.05 | -17.41 | -9.84 | -13.93 |
Diluted Net EPS (GAAP) | -6.09 | -14.05 | -17.41 | -12.85 | -14.53 |
Fiscal Year end for Inovio Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.10 | 0.39 | 0.23 | 0.11 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.10 | 0.39 | 0.23 | 0.11 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 27.49 | 35.94 | 37.26 | 44.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -27.39 | -35.55 | -37.03 | -43.96 |
Non-Operating Income | NA | 2.67 | 1.94 | 1.82 | 3.62 |
Interest Expense | NA | 0.28 | 0.31 | 0.31 | 0.31 |
Pretax Income | NA | -25.00 | -33.93 | -35.53 | -40.65 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -25.00 | -33.93 | -35.53 | -40.65 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -25.00 | -33.93 | -35.53 | -40.65 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 22.38 | 22.02 | 21.53 |
Diluted EPS Before Non-Recurring Items | NA | NA | -1.08 | -1.56 | -1.92 |
Diluted Net EPS (GAAP) | NA | -1.05 | -1.56 | -1.56 | -1.92 |